The company highlights the critical role of unified digital platforms in ensuring compliance, sponsor trust, and clinical readiness.
Austin, TX — October 3, 2025 — L7 Informatics is urging contract development and manufacturing organizations (CDMOs) to address a widening digital maturity gap that threatens their ability to meet sponsor expectations and bring advanced therapies to patients efficiently.
As
biopharma companies increase their digital investments, many CDMOs remain
reliant on manual processes and fragmented systems. This divide is emerging at
the worst possible time: sponsors are consolidating networks, regulatory
scrutiny is intensifying, and therapies are becoming more complex to
manufacture and scale.
“From
my perspective, working earlier in my career in biotech, pharma, and now
alongside CDMOs, I’ve seen digital maturity evolve from a competitive edge into
a necessity,” said Marcia Blackmoore, VP of Customer Operations at L7
Informatics. “Manual processes delay technology transfer, siloed systems
create compliance risks, and fragmented data erodes sponsor confidence. The
CDMOs embracing unified platforms are the ones positioning themselves for
long-term growth and patient impact.”
L7
Informatics points to digital unified platforms as the most effective way for
CDMOs to close the gap. Unlike piecemeal tools, unified platforms integrate
critical functions (such as ELN, LIMS, MES, scheduling, and analytics) into a
single contextualized framework. Beyond eliminating paper, they orchestrate
workflows, embed quality into everyday operations, and lay the foundation for
AI readiness.
A
recent Contract Pharma webinar, “Cell Therapy at Scale: Digitalizing
Manufacturing for Compliance and Efficiency” re-emphasized the need for
digital maturity. During the session, Blackmoore and Cellipont’s COO, Mike
O’Mara, discussed how CDMOs can scale manufacturing while ensuring compliance
and efficiency. The conversation highlighted that unified platforms are not a
future ambition; they are already transforming operations today.
For
CDMOs, the message is clear: closing the maturity gap is not optional. By
approaching digital transformation as a stepwise journey, built on a unified
foundation, CDMOs can strengthen sponsor partnerships, accelerate time to
clinic, and deliver therapies with confidence.
Additional
Resources: Read
the full article: Closing the Digital Maturity Gap: https://l7informatics.com/blog/closing-the-digital-maturity-gap/ Watch
the Contract Pharma webinar featuring L7 Informatics and Cellipont BioServices:
https://l7informatics.com/webinar/contract-pharma-webinar-cell-therapy-at-scale-digitalizing-manufacturing-for-compliance-and-efficiency/
About
L7 Informatics For
more information, visit L7INFORMATICS.com.
Media
Contact
Founded in 2012
and headquartered in Austin, TX, L7 Informatics is redefining digital
transformation in life sciences with L7|ESP, the Enterprise Science Platform
built to unify data, orchestrate and automate workflows, and enable AI
operations across R&D, CMC, manufacturing, QC, diagnostics, and clinical
environments. L7|ESP connects the dots between disparate instruments, software,
and teams by providing a single digital scientific platform with flexible data
modeling, extensive API integrations to fit seamlessly into any ecosystem, and
a full suite of built-in applications, including LIMS, ELN, MES, Inventory, and
Scheduling.
Jessica Tobey
L7 Informatics
jessica.tobey@l7informatics.com
